Researchers have identified distinct biological targets and protective mechanisms in metabolic dysfunction-associated steatotic liver disease, offering new pathways for experimental therapies as scientists work toward clinical testing for millions of affected patients.
Texas A&M Researchers Target MAP4K4 With Experimental Compound GPPD
For millions of people living with metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease, treatment options remain restricted to patients with advanced disease who often face common side effects. Excess fat accumulation in the liver drives inflammation, tissue damage, and fibrosis—scar tissue buildup that can trigger cirrhosis, liver failure, and the need for a transplant. Now, new research from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) published in JHEP Reports has identified a promising new therapeutic target.
Instead of focusing on traditional avenues, Dr. Adi Joshi and his research team investigated MAP4K4, a protein involved in several major biological pathways. The team determined that MAP4K4 levels increase as liver disease advances, making it a viable candidate for intervention. Working alongside collaborators at the University of Oklahoma, the researchers tested an experimental small-molecule inhibitor called GPPD.
Unlike therapies that attempt to remove the protein entirely, GPPD selectively blocks its activity while potentially preserving its normal functions.
Joshi added that GPPD is unique because it decreases the protein’s activity without changing its overall levels, which may help preserve its normal functions while still providing therapeutic benefit.
Preclinical Results Show Reduction in Fat, Inflammation, and Scarring
Testing in preclinical models revealed that GPPD simultaneously improved several defining characteristics of MASH. Traditional experimental therapies frequently focus on a single aspect, such as reducing liver fat. However, MASH develops through multiple interconnected biological processes.
According to findings highlighted by Texas A&M Stories, the compound successfully attenuated fat accumulation, inflammation, liver injury, and fibrosis.
Cedars-Sinai Study Identifies UBE2N Enzyme as a Natural Liver Protector
In a separate multicenter study published in Nature Metabolism, investigators co-led by Cedars-Sinai Health Sciences University uncovered a distinct protective mechanism involving the UBE2N enzyme. An estimated 100 million people in the U.S. have metabolic dysfunction-associated steatotic liver disease (MASLD), according to the American Liver Foundation, with roughly 20% to 25% progressing to MASH.
Previous research pointed to damaged mitochondria—the energy-producing structures inside cells—as a primary driver of the condition. The Cedars-Sinai team found that levels of UBE2N decline in liver cells as the disease worsens.
Dr. Ekihiro Seki noted that when enzyme levels fell, researchers observed increased cell damage and liver injury. When investigators restored UBE2N to normal levels in laboratory mice, fat accumulation, inflammation, and scarring decreased.
Researchers Prepare Safe Dosing Levels for Human Trials
Both research groups are laying the groundwork for eventual human testing, though their approaches target different biological levers. For the Texas A&M compound, toxicology studies have shown no evidence of significant toxicity so far. Before human trials begin, the team is conducting pharmacokinetic studies to understand how the body absorbs, distributes, and processes GPPD, which will determine safe and effective dosing levels.
Meanwhile, Cedars-Sinai researchers point out that enhancing the UBE2N protective pathway could eventually complement existing treatments and help identify patients most likely to benefit.
These critical preclinical evaluations will ultimately pave the way for future clinical applications aimed at improving outcomes for patients battling this challenging disease.